Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

High levels of a lipoprotein that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have multiple drugs to treat it Why seemingly healthy Indians in their ...

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.